Ascendis Pharma (ASND) PT Raised to $189 at Wedbush, Following Clinical Business Update
Tweet Send to a Friend
Wedbush analyst Liana Moussatos raised the price target on Ascendis Pharma (NASDAQ: ASND) to $189.00 (from $186.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
